Fig. 3
From: Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation
Clusterin reduces the severity of tau pathology. a Representative images from the cortical and hippocampal regions of 6-month-old CLU WT-TauP301L and CLU KO-TauP301L showing tau pathology. Tau hyperphosphorylation at serine 202, serines 396/404, and tau conformational change were detected by using CP-13, PHF-1, and MC-1, respectively. Scale bar, 100 μm. b Quantitative analysis of tau accumulation in cortex and hippocampus of CLU WT-TauP301L and CLU KO-TauP301L mice. For the CP-13, PHF-1 and MC-1 analyses n = 23–28 mice/group were used. Data presented as mean ± S.E.M. and analyzed with Student’s t test, *p < 0.05. c Biochemical evaluation of the total tau levels in the TBS-soluble (S1) and sarkosyl-soluble (S2) fractions. N = 22–25 mice/group. Data present as mean ± S.E.M. and analyzed with Student’s t test, *p < 0.05. d The levels of total and hyperphosphorylated tau were assessed by the immunoblotting analysis. N = 12 mice/group. Data present as mean ± S.E.M. and analyzed with Student’s t test, *p < 0.05